Acemoglu, D., and Linn, J. (2004). Market size in innovation: Theory and evidence from the pharmaceutical
industry. The Quarterly Journal of Economics, 119 (3) August, 1049-1090
Acemoglu, D., and Johnson S. (2006). Disease and development: The effect of life expectancy on economic
growth. NBER Working Paper 12269
Alleyne, G. and Cohen, D. (2002). The report of working group of the commission on macroeconomics and
health. WHO Commission on Macroeconomics and Health, (April).
Berndt, R.E., Glennerster, R., Kremer, M., Lee, J., Levine, R., Weizsacker, G., and Williams, H. (2007).
Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness.
Health Economics, 16(1):491-511, January
Bloom, D. E., and Sachs, J. (1998). Geography, demography and economic growth in Africa. Brookings
Papers Econ. Activity, (2): 207-295.
Chin J., Grossman, G. (1990). Intellectual property rights and North-South trade. in Jones, R., and Krueger
(Ed.) The Political Economy of International Trade: Essays in Honor of Robert E. Baldwin (pp. 90-108). Cambridge:
Basil Blackwell
Christie, A. F. and Rotstein F. (2007). Duration of patent protection: Does one size fit all? University of
Melbourne Legal Studies Research Paper No. 245; Intellectual Property Research Institute of Australia Working
Paper No. 04.07. Available at SSRN: http://ssrn.com/abstract=1012214
Civan, A., and Maloney, M. (2006). The determinants of pharmaceutical research & development investments.
Contributions to Economic Analysis & Policy, No. 1, Jan
Civan, A., Maloney, M. (2007). The effect of price on pharmaceutical R&D. manuscript (2007).
Civan, A., and Koksal, B. (2008). The effect of newer drugs on health spending: Do they really increase the
costs? Available at SSRN: http://ssrn.com/abstract=1068909
Cohen, R., , Nelson, R., and Walsh, J. (2000). Appropriability conditions and why firms patent and why they
do not in the American manufacturing sector. NBER Working Paper 7552
Deardoff A.V. (1992). Welfare effects of world patent protection. Economica, 59(233) February, 33-51.
DiMasi, J.A., Hansen, R.W., and Grabowski, H.G. (2003). The price of innovation: New estimates of drug
development costs. Journal of Health Economics, 22(2) March, 151-85.
Pécoul, B., Chirac, P., Trouiller P., Pinel, J. (1999). Access to essential drugs in poor countries: A lost battle?
Journal of American Medical Association, 281
Diwan, I., and Rodrik, D. (1991). Patents, appropriate technology and North-South trade. Journal of
International Economics, 30(1-2) February, 27-47
Gallup, J.L., and Sachs, J.D. (2001). The economic burden of malaria. Amer. J. Tropical Medicine and
Hygiene, 64, 1 Suppl. : 85-96.
Helpman, E. (1993). Innovation, imitation and intellectual property rights. Econometrica, 61(6) November,
1247- 1280.
Kremer, M. (2000). Creating markets for new vaccines. Part I: rationale. Cambridge: Harvard University
Kotowitz, Y., and Schure, P. (2006). The optimal patent length. University of Victoria, Canada, available at
http://economics.huji.ac.il/seminars/seminars%2005-06/schure.pdf.
Lanjouw, J. (1993). Patent protection in the shadow of infringement: Simulation estimations of patent value’,
Mimeograph, Department of Economics, Yale University, cited in T. O’Donoghue, S. Scotchmer and J-F Thisse,
Patent breadth, patent life and the pace of technological progress. Journal of Economics and Management
Strategy 7(1)
Lanjouw, J.O. (2002). A patent policy for global diseases: US and international legal issues. Harvard Journal
of Law and Technology, 16(1):85-124.
Lanjouw, J.O. (2004). Outline of the foreign filing license approach. Washington: Brookings Institution.
Lanjouw, J.O., and Cockburn, I.M. (2001). New pills for poor people? Empirical evidence after GATT.
World Development, 29(2) February, 265-289.
Lanjouw, J.O., and MacLeod, M. (2005). Statistical trends in pharmaceutical research for poor countries.
CIPIH Working Paper
Lemley, M. (2001). Rational ignorance at the patent office. Northwestern University Law Review, 1495-1503.
Levin, C.T., Klevorick, A.K., Nelson, R.R., and Winter, S.G. (1987). Appropriating the returns from industrial
R&D. Brookings Papers on Economic Activity, 3: pp. 783-820
Lichtenberg, F. (1996). Do (more and better) drugs keep people out of hospitals? The American Economic
Review Papers and Proceeding, 86(2), 384-388.
Lichtenberg, F. (2001). Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS.
Health Affairs, 20(5), 241-51.
Lichtenberg, F. (2005). Pharmaceutical innovation and the burden of disease in developing and developed
countries. Journal of Medicine and Philosophy, 30(6), December
Lorentzon, P., McMillan, J., and Wacziarg, R. (2005). Death and development. NBER Working Paper 11620
Mansfield, E. (1986). Patents and innovation: An empirical study. Management Science, 31
Pakes, A., and Simpson, M. (1989). Patent renewal data. Brookings Papers on Economic Activity:
Microeconomics, 331, 391.
Schankerman, M. (1998). How valuable is patent protection? Estimates by technology Field. The RAND
Journal of Economics, 29(1)
Schumpeter, J. (1942). Capitalism, Socialism, and Democracy. New York: Harper & Row
So, A., Rai, Arti, K., and Cook-Deegan, Robert M. (2005). Intellectual property rights and technology transfer:
enabling access for developing countries. (Commissioned Report, World Health Organization).
Taylor, C.T., Silberston, Z.A. (1973). The Economic Impact of the Patent System. Cambridge, England:
Cambridge University Press
Towse, A., Mestre-Ferrandiz J., and Renowden, O. (2004). Estimates of the medium-term financial resource
needs for development of pharmaceuticals to combat ‘neglected diseases. Geneva: The initiative on Public-
Private Partnerships for Health, Global Forum for Health Research.
Young, A. (2005). The gift of the dying: The tragedy of AIDS and the welfare of future African generations.
Quarterly Journal of Economics, 120(2), 423-466.
Thank you for copying data from http://www.arastirmax.com
